View Clinical Trial (Medical Research Study)
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
| City: |
|
Overland Park |
| State: |
|
Kansas |
| Zip Code: |
|
66215 |
| Conditions: |
|
Acute Gouty Arthritis |
| Purpose: |
|
This is a 36 week open-label extension of the canakinumab pre-filled syringe study for
safety and tolerability in patients who have frequent flares of acute gouty arthritis.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion criteria:
- Compliance and completion of the canakinumab PFS core study
- Unchanged significant clinical medical history from entry into core study
Exclusion criteria:
- Physician judgment of unsuitability for the study
- Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may
apply
|
| NCT ID: |
|
NCT01431638 |
| Primary Contact: |
|
Study Director
Novartis Pharmaceticals
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Phone: 862-778-8300
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Overland Park, Kansas 66215
United States
Novartis Pharmaceuticals
Phone: 862-778-8300
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|